

# Hannah Bower

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3375489/hannah-bower-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

649  
citations

10  
h-index

25  
g-index

30  
ext. papers

927  
ext. citations

3.7  
avg, IF

4.25  
L-index

#	Paper	IF	Citations
29	Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2851-7	2.2	390
28	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. <i>Leukemia</i> , <b>2018</b> , 32, 2203-2210	10.7	43
27	Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e390	7	41
26	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	37
25	Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1419-1426	8.7	30
24	Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 169-175	2.4	21
23	The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , <b>2017</b> , 102, F131-F135	4.7	12
22	Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 828-836	3.8	10
21	Capturing simple and complex time-dependent effects using flexible parametric survival models: A simulation study. <i>Communications in Statistics Part B: Simulation and Computation</i> , <b>2019</b> , 1-17	0.6	10
20	Strcs: A Command for Fitting Flexible Parametric Survival Models on the Log-hazard Scale. <i>The Stata Journal</i> , <b>2016</b> , 16, 989-1012	3.5	10
19	Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenarios. <i>Breast</i> , <b>2019</b> , 45, 75-81	3.6	8
18	Loss in working years after a breast cancer diagnosis. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 738-743	8.7	6
17	Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age. <i>Breast</i> , <b>2019</b> , 45, 48-55	3.6	5
16	Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. <i>CKJ: Clinical Kidney Journal</i> , <b>2020</b> , 13, 821-827	4.5	4
15	Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 182, 699-707	4.4	3
14	OP0034 DOES THE RISK OF VENOUS THROMBOEMBOLISM VARY WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 23.2-24	2.4	3
13	Asthma and all-cause mortality in children and young adults: a population-based study. <i>Thorax</i> , <b>2020</b> , 75, 1040-1046	7.3	3

12	Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. <i>Rheumatology</i> , <b>2021</b> ,	3.9	3
11	Temporal Trends in Chronic Myeloid Leukemia Outcome Using the Loss in Expectation of Life: A Swedish Population-Based Study. <i>Blood</i> , <b>2015</b> , 126, 2779-2779	2.2	2
10	Frailty trajectories in three longitudinal studies of aging: Is the level or the rate of change more predictive of mortality?. <i>Age and Ageing</i> , <b>2021</b> , 50, 2174-2182	3	2
9	Reply to D. Pulte et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 696-697	2.2	1
8	Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
7	POS0601 DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 535.2-535	2.4	1
6	POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 864-865	2.4	1
5	Potential bias introduced by not including multiple time-scales in survival analysis: a simulation study. <i>Communications in Statistics Part B: Simulation and Computation</i> , 1-14	0.6	1
4	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
3	Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis.. <i>Scandinavian Journal of Rheumatology</i> , <b>2022</b> , 1-7	1.9	0
2	Risk of Bleeding in 9,429 Patients with Philadelphia-Negative Myeloproliferative Neoplasms: a Population-Based Study from Sweden. <i>Blood</i> , <b>2016</b> , 128, 946-946	2.2	
1	Assessing the impact of including variation in general population mortality on standard errors of relative survival and loss in life expectancy.. <i>BMC Medical Research Methodology</i> , <b>2022</b> , 22, 130	4.7	